P=N/A, N=180, Recruiting, Pfizer | Trial completion date: Oct 2025 --> Jan 2026 | Trial primary completion date: Oct 2025 --> Jan 2026

The patient was treated sequentially with three generations of EGFR TKIs-gefitinib, osimertinib, and dacomitinib-while continuing immunosuppressive therapy for graft function. To our knowledge, this is the first reported case of an EGFR L747P-mutated lung adenocarcinoma in a renal transplant recipient benefiting from sequential multi-TKI therapy. This case underscores the importance of vigilant cancer surveillance in transplant recipients and suggests that individualized TKI sequencing may offer clinical benefit, although further evidence is required.

P1, N=29, Terminated, Taiho Oncology, Inc. | Completed --> Terminated; After careful review of Taiho's ongoing portfolio and data obtained so far in the context of broader landscape of clinical development in NSCLC HER2mut, Sponsor has made a strategic decision to terminate this study and not based on safety concerns.

P=N/A, N=180, Recruiting, Pfizer | Trial completion date: Mar 2026 --> Oct 2025 | Trial primary completion date: Mar 2026 --> Oct 2025

This study highlights the role of FAM in IS, identifies VIM, G0S2, and GPR84 as novel diagnostic biomarkers, and positions GPR84 as a therapeutic target, thereby advancing precision diagnosis and treatment.

P2, N=30, Active, not recruiting, Shanghai Chest Hospital | Recruiting --> Active, not recruiting | Trial completion date: Dec 2022 --> Dec 2027

The drug sensitivity analysis showed that dacomitinib and talazoparib may serve as anti-ESCC drugs through targeting MAPK14. The in vitro experiments showed that knockdown of NEURL3 inhibited the proliferation and motility of ESCC cells. Based on the URGs and DRGs prognostic signature, a novel nomogram was constructed that could serve as a potentially reliable prognostic model and provide theoretical basis for uncovering potential therapeutic target in the treatment of ESCC.

Dacomitinib demonstrated robust systemic and intracranial efficacy in patients with NSCLC harboring EGFR mutations and severe brain metastases, with acceptable adverse events, thereby supporting its use as a first-line treatment.

P1, N=29, Completed, Taiho Oncology, Inc. | Active, not recruiting --> Completed | Trial primary completion date: May 2025 --> Jan 2025

P=N/A, N=180, Recruiting, Pfizer | Enrolling by invitation --> Recruiting

P1/2, N=35, Completed, The Netherlands Cancer Institute | Unknown status --> Completed

This work represents the first cross-species metabolic investigation of canertinib, providing critical insights into interspecies metabolic disparities. The elucidated metabolic framework advances mechanistic understanding of the compound's pharmacological activity and toxicity profiles.